This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

NCT00720603 ↗

Expanded access No longer available Genzyme, a Sanofi Company

Summary

The purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Plerixafor	Small molecule	240 ug/kg	Subcutaneous

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

Summary

Timeline

Drugs

Indications